EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus

Chris Rundfeldt, Pavel Klein iD, Detlev Boison, Alexander Rotenberg, Raimondo D'Ambrosio, Cliff Eastman, Benton Purnell, Madhuvika Murugan, Howard P Goodkin, Wolfgang Löscher iD

Epilepsia · 2023

DOI: 10.1111/epi.17520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2023. Verfasst von Chris Rundfeldt und 9 weiteren Autor:innen. Beteiligte Einrichtung: PrevEp Inc., Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Status Epilepticus. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

For an antiseizure medication (ASM) to be effective in status epilepticus (SE), the drug should be administered intravenously (i.v.) to provide quick access to the brain. However, poor aqueous solubility is a major problem in the development of parenteral drug solutions. Given its multiple mechanisms of action, topiramate (TPM) is a promising candidate for the treatment of established or refractory SE, as supported by clinical studies using nasogastric tube TPM administration. However, TPM is not clinically available as a solution for i.v. administration, which hampers its use in the treatment of SE. Here, we describe a novel easy‐to‐use and easy‐to‐prepare i.v. TPM formulation using the U.S. Food and Drug Administration (FDA)–approved excipient meglumine.

Methods

During formulation development, we compared the solubility of TPM in bi‐distilled water with vs without a range of meglumine concentrations. Furthermore, the solubility of combinations of TPM and levetiracetam and TPM, levetiracetam, and atorvastatin in aqueous meglumine concentrations was determined. Subsequently, the pharmacokinetics and tolerability of meglumine‐based solutions of TPM and TPM combinations were evaluated in rats, including animals following fluid percussion injury or pilocarpine‐induced SE.

Results

The amino sugar meglumine markedly enhances the aqueous solubility of TPM. A comparison with data on dissolving TPM using sulfobutylether‐β‐cyclodextrin (Captisol) demonstrates that meglumine is much more effective for dissolving TPM. Furthermore, meglumine can be used to prepare drug cocktails where TPM is co‐administered with another ASM for SE treatment. The tolerability studies of the meglumine‐based TPM solution and meglumine‐based TPM combinations in normal rats and the rat fluid percussion injury and pilocarpine‐induced SE models demonstrate excellent tolerability of the novel drug solutions. Preclinical studies on antiseizure efficacy in the SE model are underway. Significance In conclusion, the novel meglumine‐based solution of TPM presented here may be well suited for clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsStatus EpilepticusRatsAnimalsTopiramatePilocarpineLevetiracetamFructose

Stichwörter der Autor:innen

atorvastatinbenzodiazepinescyclodextrinslevetiracetamstatus epilepticus

Substanzen

TopiramateAnticonvulsantsPilocarpineLevetiracetamFructose

Autor:innen und Institutionen

  • PrevEp Inc., Bethesda, Maryland, USA.
  • Mid-Atlantic Epilepsy and Sleep Center, Bethesda, Maryland, USA.
  • Department of Neurosurgery, Robert Wood Johnson & New Jersey Medical Schools, Rutgers University, Piscataway, New Jersey, USA.
  • Division of Epilepsy and Neurophysiology, Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • FM Kirby Center for Neurobiology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Department of Neurological Surgery, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Pavel Klein, Wolfgang Löscher

Zitieren

APA

Rundfeldt, C., Klein, P., Boison, D., Rotenberg, A., D'Ambrosio, R., Eastman, C., Purnell, B., Murugan, M., Goodkin, H. P., & Löscher, W. (2023). Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. Epilepsia. https://doi.org/10.1111/epi.17520

Vancouver

Rundfeldt C, Klein P, Boison D, Rotenberg A, D'Ambrosio R, Eastman C, et al. Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus. Epilepsia. 2023. doi:10.1111/epi.17520

BibTeX
@article{Rundfeldt2023,
  author = {Rundfeldt, Chris and Klein, Pavel and Boison, Detlev and Rotenberg, Alexander and D'Ambrosio, Raimondo and Eastman, Cliff and Purnell, Benton and Murugan, Madhuvika and Goodkin, Howard P and Löscher, Wolfgang},
  title = {Preclinical pharmacokinetics and tolerability of a novel meglumine‐based parenteral solution of topiramate and topiramate combinations for treatment of status epilepticus},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17520}
}
Kostenlos starten →